- Organovo (NASDAQ:ONVO) launches its exVive3D Human Liver Tissue Model for preclinical drug discovery testing. Customers will be unable to take delivery on the product, however. It will be initially available only through the company's contract research services program.
- The model's purpose is to provide human-specific data to aid in the prediction of liver tissue toxicity or ADME outcomes in later-stage preclinical drug discovery programs.
- Shares are up 10% premarket on higher-than-average volume.